Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

• Published in: Clinical pharmacokinetics Vol. 61; no. 7; pp. 1057 - 1067
• Main Authors: Urva, Shweta, Quinlan, Tonya, Landry, John, Ma, Xiaosu, Martin, Jennifer A., Benson, Charles T.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2022; Springer Nature B.V
• Subjects: Antidiabetics; Area Under Curve; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Drug dosages; Ejection fraction; Enzymes; Fatty liver; Gastric Inhibitory Polypeptide - pharmacokinetics; GLP-1 receptor agonists; Glucagon; Glucagon-Like Peptide-1 Receptor - agonists; Heart failure; Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents - pharmacokinetics; Internal Medicine; Liver; Liver Diseases - complications; Medicine; Medicine & Public Health; Metabolism; NCT; NCT03940742; Original; Original Research Article; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Polypeptides; Serum Albumin; United States > US

Background and Objective Tirzepatide, a novel, once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is approved in the US as a treatment for type 2 diabetes and is under development for long-term weight management, heart failure with preserved...